BIO Comments to CMS on Oregon Proposed 1115 Waiver Application
April 1, 2022
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the Oregon Health Authority’s (OHA) proposed Oregon Health Plan §1115 Demonstration Waiver Application (Waiver Application), which among other things, would be a waiver of compliance with essential provisions of §1927 of the Social Security Act (SSA) to exclude drugs approved through the FDA’s accelerated approval pathway (AAP). We urge CMS to reject those provisions of the proposed waiver that would exacerbate health disparities and jeopardize patient access and care, especially for patients with rare and chronic diseases.
Download Full Comments Below
BIO Comments to CMS on OHA Proposed 1115 Waiver Application
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
We are writing to express our strong support for the bipartisan Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). The legislation, which was introduced by Reps. John Joyce (R-PA) and Wiley Nickel (D-NC) in September,1 corrects a…
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the Oregon Health Authority’s (OHA) proposed Oregon Health Plan §1115 Demonstration Waiver Application (Waiver Application), which among other things, would be a waiver of compliance with essential provisions of §1927 of the Social Security Act (SSA) to exclude drugs approved through the FDA’s accelerated approval pathway (AAP). We urge CMS to reject those provisions of the proposed waiver that would exacerbate health disparities and jeopardize patient access and care, especially for patients with rare and chronic diseases.